market outlook
नज़रिए अनुसार · 1 takes across the edition
搜狐 / Sohu (2026 biotech watch) · China · China's in-vivo gene-editing pipeline reaches the clinic
Lists in-vivo gene editing among 2026's top biotech themes, noting YolTech's YOLT-201 (ATTR-PN/CM) won clinical approval in March as China's first LNP-mediated in-vivo gene-editing drug to enter trials, and two paediatric personalised CRISPR therapies advancing.
“2026年生物医药科技10大关注点 (Ten things to watch in biomedical tech in 2026).”